TransCure bioServices delivers CDX mouse models to advance AML preclinical studies
TransCure bioServices has developed cell line-derived xenograft (CDX) mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukaemia (AML). These models enable deeper insights into the efficacy and toxicity of AML therapies, leading to the development of better treatments and bringing hope to the thousands of […]
